Methotrexate and risk for lymphoma [4]

Archives of Dermatology

Volumn 143, Issue 5, 2007, Pages 663-664

  Whitmore, S Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PSORALEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CORONARY RISK; DRUG DOSE TITRATION; DRUG MEGADOSE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; LETTER; LOW DRUG DOSE; LYMPHOMA; PRIORITY JOURNAL; PSORIASIS; RISK FACTOR; TREATMENT PLANNING; ULTRAVIOLET A RADIATION; VITAMIN SUPPLEMENTATION;

DERMATOLOGIC AGENTS; HOMOCYSTEINE; HUMANS; LYMPHOMA; METHOTREXATE; PSORIASIS; RISK FACTORS;

EID: 34249074444     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142:1132-1135.
2. Lightfoot TJ, Skibola CF, Willet EV, et al. Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev. 2005;14:2999-3003.
3. Bjørke Monsen AL, Ueland PM. Homocysteine and methylmalonic acid in diagnosis and risk assessment in infancy and adolescence. Am J Clin Nutr. 2003;78:7-21.
4. van Ede AE, Laan RF, Bloom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:658-665.
5. Malerba M, Gisondi P, Radaeli R, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006;155:1165-1169.
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.